ThyroSeq v2 Testing: Impact on Cytologic Diagnosis, Management, and Cost of Care in Patients with Thyroid Nodule
Fazeli S, Zehr B, Amraei R, Toraldo G, Guan H, Kindelberger D, Lee S, Cerda S. ThyroSeq v2 Testing: Impact on Cytologic Diagnosis, Management, and Cost of Care in Patients with Thyroid Nodule. Thyroid 2020, 30: 1528-1534. PMID: 32349630, DOI: 10.1089/thy.2019.0191.Peer-Reviewed Original ResearchConceptsAUS/FLUSCost of careIndeterminate cytology resultsThyroid nodulesThyroSeq v2Cytology resultsCytologic diagnosisFN/SFN categoriesUndetermined significance/follicular lesionMolecular testsRate of overtreatmentRate of surgeryRate of malignancyOutcome of managementFollicular neoplasm/Fine-needle aspirationIndeterminate cytologic diagnosisOverall rateFN/SFNThyroid fine-needle aspirationNovel molecular testsThyroSeq testingLack of decreaseConsecutive patientsRetrospective study
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply